{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:44:13Z","timestamp":1786981453335,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s11060-024-04861-6","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T05:49:58Z","timestamp":1732081798000},"page":"279-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update"],"prefix":"10.1007","volume":"171","author":[{"given":"Mateo","family":"Ziu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia M.","family":"Halasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya U.","family":"Kumthekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tresa M.","family":"McGranahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"issue":"1","key":"4861_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11060-005-9109-6","volume":"79","author":"H Duffau","year":"2006","unstructured":"Duffau H (2006) New concepts in surgery of WHO grade II gliomas: functional brain mapping, connectionism and plasticity\u2013a review, (in eng). J Neurooncol 79(1):77\u2013115. https:\/\/doi.org\/10.1007\/s11060-005-9109-6","journal-title":"J Neurooncol"},{"issue":"6","key":"4861_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary, (in eng). Acta Neuropathol 131(6):803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"issue":"3","key":"4861_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11060-015-1865-3","volume":"125","author":"AE Sloan","year":"2015","unstructured":"Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ (2015) The role of emerging therapy in the management of patients with diffuse low grade glioma, (in eng). J Neurooncol 125(3):631\u2013635. https:\/\/doi.org\/10.1007\/s11060-015-1865-3","journal-title":"J Neurooncol"},{"issue":"3","key":"4861_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11060-015-1931-x","volume":"125","author":"M Ziu","year":"2015","unstructured":"Ziu M, Kalkanis SN, Gilbert M, Ryken TC, Olson JJ (2015) The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline, (in eng). J Neurooncol 125(3):585\u2013607. https:\/\/doi.org\/10.1007\/s11060-015-1931-x","journal-title":"J Neurooncol"},{"issue":"3","key":"4861_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11060-016-2137-6","volume":"128","author":"M Ziu","year":"2016","unstructured":"Ziu M, Olson JJ (2016) Update on the evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: the role of initial chemotherapy, (in eng). J Neurooncol 128(3):487\u2013489. https:\/\/doi.org\/10.1007\/s11060-016-2137-6","journal-title":"J Neurooncol"},{"issue":"8","key":"4861_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary, (in eng). Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"10","key":"4861_CR7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, (in eng). J Clin Epidemiol 62(10):1006\u20131012. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.005","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"4861_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jama.2012.156703","volume":"309","author":"DF Ransohoff","year":"2013","unstructured":"Ransohoff DF, Pignone M, Sox HC (2013) How to decide whether a clinical practice guideline is trustworthy. JAMA 309(2):139\u2013140","journal-title":"JAMA"},{"issue":"11","key":"4861_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/s1470-2045(16)30313-8","volume":"17","author":"BG Baumert","year":"2016","unstructured":"Baumert BG et al (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033\u201326033): a randomised, open-label, phase 3 intergroup study, (in eng). Lancet Oncol 17(11):1521\u20131532. https:\/\/doi.org\/10.1016\/s1470-2045(16)30313-8","journal-title":"Lancet Oncol"},{"issue":"14","key":"4861_CR10","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC et al (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma, (in eng). N Engl J Med 374(14):1344\u20131355. https:\/\/doi.org\/10.1056\/NEJMoa1500925","journal-title":"N Engl J Med"},{"issue":"3","key":"4861_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11060-017-2599-1","volume":"135","author":"RS Youland","year":"2017","unstructured":"Youland RS, Kreofsky CR, Schomas DA, Brown PD, Buckner JC, Laack NN (2017) The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma, (in eng). J Neurooncol 135(3):535\u2013543. https:\/\/doi.org\/10.1007\/s11060-017-2599-1","journal-title":"J Neurooncol"},{"issue":"3","key":"4861_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ijrobp.2014.11.012","volume":"91","author":"BJ Fisher","year":"2015","unstructured":"Fisher BJ et al (2015) Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424, (in eng). Int J Radiat Oncol Biol Phys 91(3):497\u2013504. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.11.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4861_CR13","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.2147\/ott.S108989","volume":"9","author":"XJ Gai","year":"2016","unstructured":"Gai XJ, Wei YM, Tao HM, An DZ, Sun JT, Li BS (2016) Comparison of long-term survival between temozolomide-based chemoradiotherapy and radiotherapy alone for patients with low-grade gliomas after surgical resection, (in eng). Onco Targets Ther 9:5117\u20135121. https:\/\/doi.org\/10.2147\/ott.S108989","journal-title":"Onco Targets Ther"},{"issue":"6","key":"4861_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1200\/jco.2013.53.1830","volume":"32","author":"RS Prabhu","year":"2014","unstructured":"Prabhu RS et al (2014) Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98\u201302, (in eng). J Clin Oncol 32(6):535\u2013541. https:\/\/doi.org\/10.1200\/jco.2013.53.1830","journal-title":"J Clin Oncol"},{"issue":"4","key":"4861_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/coc.0000000000000519","volume":"42","author":"JM Ryckman","year":"2019","unstructured":"Ryckman JM, Appiah AK, Lyden E, Verma V, Zhang C (2019) Concurrent Versus Sequential Chemoradiation for Low-grade Gliomas Meeting RTOG 9802 Criteria, (in eng). Am J Clin Oncol 42(4):391\u2013398. https:\/\/doi.org\/10.1097\/coc.0000000000000519","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"4861_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-018-2972-8","volume":"140","author":"T Koo","year":"2018","unstructured":"Koo T et al (2018) Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15\u201302 and KROG 16\u201304 intergroup study, (in eng). J Neurooncol 140(2):445\u2013455. https:\/\/doi.org\/10.1007\/s11060-018-2972-8","journal-title":"J Neurooncol"},{"issue":"2","key":"4861_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/neuonc\/now176","volume":"19","author":"M Wahl","year":"2017","unstructured":"Wahl M et al (2017) Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide, (in eng). Neuro Oncol 19(2):242\u2013251. https:\/\/doi.org\/10.1093\/neuonc\/now176","journal-title":"Neuro Oncol"},{"issue":"2","key":"4861_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11060-014-1641-9","volume":"121","author":"W Taal","year":"2015","unstructured":"Taal W et al (2015) Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics, (in eng). J Neurooncol 121(2):365\u2013372. https:\/\/doi.org\/10.1007\/s11060-014-1641-9","journal-title":"J Neurooncol"},{"issue":"2","key":"4861_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11060-013-1106-6","volume":"113","author":"M Blonski","year":"2013","unstructured":"Blonski M et al (2013) Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients, (in eng). J Neurooncol 113(2):267\u2013275. https:\/\/doi.org\/10.1007\/s11060-013-1106-6","journal-title":"J Neurooncol"},{"issue":"5","key":"4861_CR20","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.08.025","volume":"105","author":"MC Tom","year":"2019","unstructured":"Tom MC et al (2019) Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma, (in eng). Int J Radiat Oncol Biol Phys 105(5):1106\u20131112. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4861_CR21","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/neuonc\/noab081","volume":"23","author":"Y Yu","year":"2021","unstructured":"Yu Y et al (2021) Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas, (in eng). Neuro Oncol 23(11):1872\u20131884. https:\/\/doi.org\/10.1093\/neuonc\/noab081","journal-title":"Neuro Oncol"},{"issue":"7804","key":"4861_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat M et al (2020) Mechanisms and therapeutic implications of hypermutation in gliomas, (in eng). Nature 580(7804):517\u2013523. https:\/\/doi.org\/10.1038\/s41586-020-2209-9","journal-title":"Nature"},{"issue":"2","key":"4861_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11060-017-2443-7","volume":"133","author":"W Haque","year":"2017","unstructured":"Haque W, Verma V, Butler EB, Teh BS (2017) Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma, (in eng). J Neurooncol 133(2):369\u2013375. https:\/\/doi.org\/10.1007\/s11060-017-2443-7","journal-title":"J Neurooncol"},{"issue":"2","key":"4861_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11060-014-1383-8","volume":"117","author":"G Kaloshi","year":"2014","unstructured":"Kaloshi G, Rroji A, Petrela M (2014) Upfront chemotherapy with CCNU alone for adults\u2019 low-grade gliomas: a clinical analysis, (in eng). J Neurooncol 117(2):373\u2013374. https:\/\/doi.org\/10.1007\/s11060-014-1383-8","journal-title":"J Neurooncol"},{"key":"4861_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume-title":"N Engl J Med","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023 Aug 17;389(7):589\u2013601. https:\/\/doi.org\/10.1056\/NEJMoa2304194. Epub 2023 Jun 4. PMID: 37272516; PMCID: PMC11445763"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04861-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T19:08:25Z","timestamp":1735844905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04861-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4861"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04861-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All Guideline Task Force members were required to disclose all potential COIs prior to beginning work on the guideline, using the COI disclosure form of the AANS\/CNS Joint Guidelines Review Committee. The CNS Guidelines Committee and Guideline Task Force Chair reviewed the disclosures and either approved or disapproved the nomination and participation on the task force. The CNS Guidelines Committee and Guideline Task Force Chair may approve nominations of task force members with possible conflicts and restrict the writing, reviewing, and\/or voting privileges of that person to topics that are unrelated to the possible COIs. The task force has not made any disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}